Company intelligence / Profile preview

L.E.A.F. Pharmaceuticals

Woburn, Massachusetts, United Statesleafpharmaceuticals.com ↗

Ownership: Private
Development stage: Other

Overview

As of October 2018, L.E.A.F. Pharmaceuticals received positive US FDA feedback for four lead anticancer drugs—LEAF‑1401, LEAF‑1701, LEAF‑1702, and LEAF‑1703—with guidance to move all four into a single first-in-human Phase 1 clinical trial. One candidate may be eligible for registration via the FDA’s accelerated 505(b)(2) pathway. The company has filed over 55 patent applications since its founding in August 2014. No published clinical results yet; programs are at or near IND-enabling/early clinical stage.

Therapeutic areas: Oncology
Modalities: Small molecules (specifically onco-immuno antimetabolites)
Industry: Biotech

Drug pipeline

5 assets

LEAF-1701

Preclinical

4 more assets in the full pipeline.

Partnerships

Contract manufacturing organization partnership for production of investigational drug substance(s)

Beyond the preview

Go deeper on L.E.A.F. Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L.E.A.F. Pharmaceuticals.